Questcor Pharmaceuticals (FRA:QPH) Asset Impairment Charge : €0.0 Mil (TTM As of Jun. 2014)

View and export this data going back to . Start your Free Trial

What is Questcor Pharmaceuticals Asset Impairment Charge?

Questcor Pharmaceuticals's Asset Impairment Charge for the three months ended in Jun. 2014 was €0.0 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2014 was €0.0 Mil.

Questcor Pharmaceuticals Asset Impairment Charge Historical Data

The historical data trend for Questcor Pharmaceuticals's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Questcor Pharmaceuticals Asset Impairment Charge Chart

Questcor Pharmaceuticals Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Asset Impairment Charge

Get a 7-Day Free Trial

Questcor Pharmaceuticals Quarterly Data
	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Questcor Pharmaceuticals Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2014 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

Questcor Pharmaceuticals Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Questcor Pharmaceuticals's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Questcor Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Questcor Pharmaceuticals Inc (FRA:QPH) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.questcor.com

Questcor Pharmaceuticals, Inc was incorporated in California in September 1992 as Cypros Pharmaceutical Corporation. In November 1999. The Company changed its name to Questcor Pharmaceuticals, Inc. The Company is a biopharmaceutical company focused on providing prescription drugs for central nervous system disorders. It is presently building a core portfolio of both marketed and development-stage products that address significant unmet medical needs. The Company seeks to develop and commercialize its own proprietary products, and is open to a range of partnering concepts in order to leverage its assets and build its portfolio. It markets H.P. Acthar Gel, an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis, and the treatment of nephrotic syndrome. H.P. Acthar Gel is not indicated for, but is also used in treating patients with infantile spasms, a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. The company also markets Doral, which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. It owns the worldwide rights for Acthar and the U.S. rights for Doral.

Questcor Pharmaceuticals Headlines

No Headlines